|
Projets |
Acronyme et titre |
Source du financement |
Phase |
|---|---|---|---|
|
|
ALCHEMIST - ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial |
Academic (PHRC N 2011) |
Under discussion |
|
|
BOKID - Bariatric Surgery for Obese Patients With Chronic Renal Insufficiency |
Academic (PHRC N 2014) |
Being carried out |
 |
COVERT MI - COlchicine for Left Ventricular Remodeling Treatment in Acute Myocardial Infarction
|
Academic PHRC N 2016 | Being set up |
|
|
EPURE TRANSPLANT - Double-blind Placebo-Controlled Randomised Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenon After Renal Tranplantation : Effect on Graft Function at 3 Months. |
Academic (PHRC inter régional 2014) |
Being set up |
|
|
ESTIM HTN - Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN |
Academic (PRME 2013) |
Under investigation |
|
|
HYPO ECMO - Effects of Induced Moderate HYPOthermia on mortality in Cardiogenic Shock Patients Rescued by Arterio-Venous Extracorporeal Membrane Oxygenation (ECMO) |
Academic (PHRC national 2015) |
Being set up |
 |
IMICRO : Ilomedin for treatment of septic shock with persistent microperfusion defects », a double-blind, randomized controlled trial: I-MICRO trial | Academic (PHRC N 2017 ) | Recruiting |
|
|
LIPS - study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to start in early 2014. |
Academic (PHRC N 2014) |
Other |
|
|
STOP OR NOT - Impact of Renin-Angiotensin System inhibitors continuation on outcome after major surgery: single blind randomized study |
Academic (PHRC N 2016) |
Being set up |
